Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GB Sciences Inc GBLX

Healthcare
GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company. It creates patented, disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. (GBSGB). The primary focus for the development of its lead program has been in evaluating suitable... see more

Recent & Breaking News (GREY:GBLX)

GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease

PR Newswire April 10, 2018

GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula

PR Newswire April 4, 2018

Pot Stocks, ETFs And Top News From The Cannabis Industry

Benzinga.com  April 2, 2018

Data Projects That the Legal Cannabis Market is in Growth Mode

PR Newswire March 29, 2018

GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues

PR Newswire March 28, 2018

Legal and Medical Cannabis Industries Are Set to Grow

PR Newswire March 22, 2018

Research Projects Sales of Legal Cannabis Products to Accelerate This Year

PR Newswire March 16, 2018

Legal Cannabis Industry Utilizes Reward Based Programs

PR Newswire March 15, 2018

GB Sciences Sponsors "Innovation in Medical Cannabis Therapies" Symposium

PR Newswire March 15, 2018

Data Show that Sales in the Legal Cannabis Market set to Expand

PR Newswire March 6, 2018

Legal Cannabis and CBD Sales are on the Rise

PR Newswire March 2, 2018

Sales of Legal Cannabis Products Continues to Accelerate

PR Newswire February 27, 2018

GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project

PR Newswire February 27, 2018

Legal Cannabis Market Projected to Grow With Consumer Spending

PR Newswire February 22, 2018

GB Sciences Receives Issuance of Its Cannabis Oil Production License

PR Newswire February 21, 2018

Research Shows the Growth of Legal Cannabis Sales

PR Newswire February 8, 2018

John Poss, Chief Executive Officer of GB Sciences, Inc., Returns to Uptick Newswire’s “Stock Day” Podcast with Everett Jolly for Operational Update

GlobeNewswire February 6, 2018

GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More

PR Newswire February 5, 2018

Legal Cannabis Market Growth in North America

PR Newswire February 2, 2018

GB Sciences Welcomes Dr. Zoltan Mari, A Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board

PR Newswire January 25, 2018